Sequoia Financial Advisors LLC Purchases 2,222 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sequoia Financial Advisors LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,489 shares of the medical device company’s stock after acquiring an additional 2,222 shares during the period. Sequoia Financial Advisors LLC’s holdings in DexCom were worth $660,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Blue Whale Capital LLP grew its holdings in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares during the last quarter. Motley Fool Asset Management LLC grew its holdings in DexCom by 168.7% during the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after acquiring an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new position in DexCom in the 4th quarter valued at approximately $3,334,000. Congress Asset Management Co. raised its stake in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock worth $18,085,000 after purchasing an additional 222,548 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,657 shares of company stock worth $8,019,422 in the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.9 %

NASDAQ DXCM opened at $71.35 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50 day moving average price of $83.82 and a 200-day moving average price of $76.94. The company has a market cap of $27.88 billion, a price-to-earnings ratio of 49.90, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on DXCM. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup boosted their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.